Report Code: A00496 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Multiple sclerosis (MS) is an inflammatory disease of nervous system, which is also referred as disseminated sclerosis. Multiple sclerosis is progressed with disruption spinal cord and brain nerve cells, which results in loss of ability of the parts of the nervous system to communicate including various other mental, physical and psychiatric problems. Primary progressive multiple sclerosis (PPMS) is the type of multiple sclerosis in which neurological functions are steadily deteriorated with minimal distinct relapses (exacerbations and attacks) or the fixed period remissions. The progression rates of PPMS may vary from person to person and over the timeframes, which may show the signs of transitory improvements, however, the progression of disease remains persistent. Currently, PPMS market is facing lucrative growth owing to the rising incidences of multiple sclerosis worldwide. Increasing patients’ base may promote the future growth of this market.
Presently, various types of relapsing multiple sclerosis are gradually affecting the large number of populations worldwide, e.g., secondary-progressive multiple sclerosis, relapsing remitting multiple sclerosis, primary progressive multiple sclerosis, and progressive relapsing multiple sclerosis. According to multiple sclerosis web portal (by Health Union, United States), more than 2.5 million people are affected by multiple sclerosis globally. Among all types of multiple sclerosis, 10–15% patients suffer from PPMS. It is difficult to treat as well as diagnose these patients. Hence, elevated demand for the advanced therapeutic treatment will fuel the growth of PPMS market.
Geographically, North America and Europe would be the lucrative segment for the growth of this market owing to the high prevalence rates of multiple sclerosis and rising demands for therapeutic medications for the effective treatment of PPMS in these regions. According to multiple sclerosis portal, ~500,000 people are affected with multiple sclerosis in Europe and ~400,000 affected population is present in the United States.
KEY BENEFITS
Primary Progressive Multiple Sclerosis Market Report Highlights
Aspects | Details |
---|---|
By Type |
|
By LOCATION OF TREATMENT |
|
By GEOGRAPHY |
|
Key Market Players | Tysabri, Mallinckrodt Pharmaceuticals, Sanofi, Roche, Teva Pharmaceuticals, Abbvie, Ocrevus, Merck, Novartis, Biogen |
Loading Table Of Content...
Start reading.
This Report and over 71,295+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers